Groundbreaking Technology and Innovation

YAG Laser Treats Floaters

We insist on caring for our patients with the latest technology and most advanced surgical and diagnostic methods.

We recognize that the prevalence of eye disease is increasing as our population ages and that expectations for better outcomes in eye care are increasing, too.

At Moore, we strive to provide the best patient care possible through continued medical education and innovation. The list of state-of-the-art equipment used at Moore Eye Institute daily is extensive. In Pennsylvania and internationally, we introduced some of the most important diagnostic tests for those with macular degeneration and diabetes.

More Than 25 Years Of Innovation At Moore

1990
  • Moore Eye Institute surgeons are the first in Pennsylvania to perform indirect laser surgery for retinal conditions.
1992
  • Moore Eye Institute is one of the first in the United States to introduce digital indocyanine green angiography (ICG), which is used to diagnose and monitor retinal damage and hemorrhaging.
1993
  • Moore is one of the first two practices in Pennsylvania to introduce perfluorocarbon in vitrectomy for patients with severe proliferative diabetic retinopathy.
  • Moore is one of the first three practices in Pennsylvania to treat neovascular membranes in polypoidal choroidal vasculopathy (PCV) patients.
1994
  • Moore is one of the first in Pennsylvania to perform diode laser treatment for macular degeneration; the leading cause of severe vision loss for people over age 60.
1995
  • Moore Eye Institute specialists are the first in Pennsylvania to introduce the Scanning Laser Ophthalmoscope (SLO) for glaucoma, macular degeneration and other retinal disorders. The SLO is the first generation of technology to produce 3D images of the eye used to detect aberrations and monitor disease progression.
1997
  • Moore Eye Institute is first in Pennsylvania to use Optical Coherence Tomography (OCT), technology the most important test in following patients with diabetic macular edema and macular degeneration.
  • Moore Eye Institute is first in the tri-state area to use the Iridex IQ 577nm with its MicroPulse/TxCell delivery system to treat retinal disorders.
2000
  • Moore specialists are first to perform photodynamic therapy after FDA approval in Pennsylvania for wet age-related macular degeneration.
2010
  • Moore is among the first to introduce the Pentacam nuclear density scan, the most advanced corneal tomography technology available for cataract surgery and refractive screening. Scans performed with the Pentacam display corneal aberrations and allow surgeons to make optimal lens selections for surgical patients.
  • Moore is among the first to introduce Heidelberg SPECTRALIS diagnostic technology in Pennsylvania. This advanced imaging system provides clinicians with unique views of eye structure and function to support new therapies for treating disease.
2015
  • Moore Eye Institute’s founder, Dr. Ginsburg introduced his patent-pending medical review table. This innovative tool displays a patient’s entire medical history record at a glance and captures critical details of diagnostic testing, medical conditions, office visits, and surgeries. This software technology compiles the entire medical record into a concise display for optimized patient care.

Navigate to:

We accept the following insurances:

Note: If your payer is not listed, please call our office as we accept most local insurance plans.

×